BioAge, obesity
BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic. | BioAge Labs is eyeing about $180 million in initial proceeds from an IPO and a private placement,
Obesity drug developer BioAge raises $198m in IPO
BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.
Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO
Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...
BioAge, BKV shares end their first trading day flat after earlier gains
Obesity-drug developer BioAge held on to a slim gain after rising more than 20%, while Texas-based Barnett Shale driller BKV ...
FierceBiotech4d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
BioAge Labs Inc.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with ...
Ryan Reynolds's MNTN Explores Going Public, as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
BioAge posts double-digit percentage gain after IPO; natural-gas producer BKV rises in debut
Obesity-drug developer BioAge jumps nearly 30% while Texas-based Barnett Shale driller BKV posts smaller gain.